BeiGene Net Change in Investments - Total 2014-2024 | ONC
BeiGene annual/quarterly net change in investments - total history and growth rate from 2014 to 2024. Net change in investments - total can be defined as the total change in long term and short term investments
- BeiGene net change in investments - total for the quarter ending September 30, 2024 was $0.003B, a 99.53% decline year-over-year.
- BeiGene net change in investments - total for the twelve months ending September 30, 2024 was $0.664B, a 78.28% decline year-over-year.
- BeiGene annual net change in investments - total for 2023 was $0.656B, a 57.56% decline from 2022.
- BeiGene annual net change in investments - total for 2022 was $1.546B, a 61.82% increase from 2021.
- BeiGene annual net change in investments - total for 2021 was $0.956B, a 64.93% decline from 2020.
BeiGene Annual Net Change in Investments - Total
(Millions of US $) |
| 2023 |
$656 |
| 2022 |
$1,546 |
| 2021 |
$956 |
| 2020 |
$2,724 |
| 2019 |
$713 |
| 2018 |
$-458 |
| 2017 |
$-318 |
| 2016 |
$-198 |
| 2015 |
$-54 |
| 2014 |
$-31 |
| 2013 |
$ |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
